v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
COSTS AND EXPENSES:    
Research and development $ 18,422 $ 15,327
General and administrative 8,014 5,409
  26,436 20,736
Operating loss (26,436) (20,736)
Interest and other income, net 19 83
Net loss $ (26,417) $ (20,653)
Net loss per common share, basic $ (0.05) $ (0.07)
Net loss per common share, diluted $ (0.05) $ (0.07)
Weighted average common shares outstanding, basic 522,060,899 290,106,510
Weighted average common shares outstanding, diluted 522,060,899 290,106,510

Source